RxDoctor Payments Data

Ingrid Chung, MD

Internal Medicine · Chantilly, VANPI 1073622742

Payments from drug & device makers

$678in general payments, 2019–2025

Across 20 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$208
  • AstraZeneca$133
  • Amgen$122
  • GSK$115
  • Novo Nordisk$83
  • Takeda Pharmaceuticals U.S.A., Inc.$17

What the payments were for

  • Food & beverage$678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead10$208
AstraZeneca2$133
Amgen1$122
GSK1$115
Novo Nordisk5$83
Takeda Pharmaceuticals U.S.A., Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$678 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$120,390
Medicare patients
148
Services billed
2,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$53,265
EliquisApixaban38$48,330
FarxigaDapagliflozin Propanediol28$47,652
ProliaDenosumab12$20,795
JanumetSitagliptin Phos/Metformin Hcl13$20,299
Breo ElliptaFluticasone/Vilanterol15$9,885
Atorvastatin Calcium302$2,747
Simvastatin216$1,733
Metformin Hcl192$1,425
Tamsulosin Hcl97$1,290
Amlodipine Besylate174$1,024
Rosuvastatin Calcium62$972
Levothyroxine Sodium105$879
Ezetimibe21$844
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide68$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$133$47,65228 claims
AmgenProlia$122$20,79512 claims
GSKBreo Ellipta$115$9,88515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Chantilly

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →